MP:0001800 | abnormal humoral immune response | "abnormal immune function mediated by antibodies" [Immunobiology , The Immune System in Health and Disease:ISBN 0-8153-1691-7] |
Show
Allelic Composition: Adora1tm1Rgrn/Adora1tm1Rgrn Genetic Background: involves: 129S4/SvJae * C57BL/6
|
MP:0002423 | abnormal mast cell physiology | "anomalous response of the granulated cells found in most tissues and which contain large amounts of histamine and heparin in granules" [MeSH:National Library of Medicine - Medical Subject Headings , 2003] |
Show
Allelic Composition: Cd247tm1Lov/Cd247tm1Lov,Fcer1gtm1Rav/Fcer1gtm1Rav Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt Genetic Background: involves: 129 * BALB/c
Allelic Composition: Fcer1atm1Ftl/Fcer1atm1Ftl Genetic Background: CBy.129S2-Fcer1atm1Ftl
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt,Fcer2atm1Max/Fcer2atm1Max Genetic Background: B6.Cg-Fcer1atm1Knt Fcer2atm1Max
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt,Fcer2atm1Max/Fcer2atm1Max,Fcgr1tm1Jsv/Fcgr1tm1Jsv,Fcgr2btm1Ttk/Fcgr2btm1Ttk,Fcgr3tm1Jsv/Fcgr3tm1Jsv Genetic Background: B6.Cg-Fcgr2btm1Ttk Fcgr3tm1Jsv Fcer1atm1Knt Fcgr1tm1Jsv Fcer2atm1Max
|
MP:0002451 | abnormal macrophage physiology | "abnormal function or response of the phagocytic leukocytes involved in innate immunity, early non-adaptive phases of host-defense, antigen presentation, and which act as effector cells in humoral and cell-mediated immunity" [Immunobiology , The Immune System in Health and Disease:ISBN 0-8153-1691-7, cwg:Carroll-Ann W. Goldsmith , Mouse Genome Informatics curator] |
Show
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt,Fcer2atm1Max/Fcer2atm1Max Genetic Background: B6.Cg-Fcer1atm1Knt Fcer2atm1Max
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt,Fcer2atm1Max/Fcer2atm1Max,Fcgr1tm1Jsv/Fcgr1tm1Jsv,Fcgr2btm1Ttk/Fcgr2btm1Ttk,Fcgr3tm1Jsv/Fcgr3tm1Jsv Genetic Background: B6.Cg-Fcgr2btm1Ttk Fcgr3tm1Jsv Fcer1atm1Knt Fcgr1tm1Jsv Fcer2atm1Max
|
MP:0002531 | type I hypersensitivity reaction | "a reaction manifested by localized or generalized reaction that occurs immediately (minutes) after exposure to an antigen to which the person/animal was previously sensitized; it is IgE-mediated, and mast cell activation and degranulation are hallmarks" [Pathology , 2nd edition:ISBN 0-397-51047-0] |
Show
Allelic Composition: Suz12tm1Hko/Suz12tm1Hko Genetic Background: Not Specified
|
MP:0003070 | increased vascular permeability | "greater or faster ability of the blood vessels to permit the passage of substances such as fluid, heat, or gases" [Stedman s Medical Dictionary, 27th edition:ISBN 0-683-40008-8] |
Show
Allelic Composition: Suz12tm1Hko/Suz12tm1Hko Genetic Background: Not Specified
|
MP:0003423 | reduced thrombolysis | "reduced ability or inability to break up (lyse) blood clots that are restricting the blood flow" [anna:Anna Anagnostopoulos, Mouse Genome Informatics Curator, J:17427] |
Show
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt Genetic Background: involves: 129 * BALB/c
|
MP:0005012 | decreased eosinophil count | "fewer than normal eosinophil numbers " [cwg:Carroll-Ann W. Goldsmith , Mouse Genome Informatics curator] |
Show
Allelic Composition: Fcer1atm1Ftl/Fcer1atm1Ftl Genetic Background: CBy.129S2-Fcer1atm1Ftl
|
MP:0005596 | increased susceptibility to type I hypersensitvity reaction | "greater likelihood of developing a response manifested by localized or generalized reaction that occurs immediately (minutes) after exposure to an antigen to which the person/animal was previously sensitized; it is IgE-mediated, and mast cell activation and degranulation are hallmarks" [Pathology:ISBN 0-397-51047-0, cwg:Carroll-Ann W. Goldsmith , Mouse Genome Informatics curator] |
Show
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt Genetic Background: involves: 129 * BALB/c
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt,Fcer2atm1Max/Fcer2atm1Max,Fcgr1tm1Jsv/Fcgr1tm1Jsv,Fcgr2btm1Ttk/Fcgr2btm1Ttk,Fcgr3tm1Jsv/Fcgr3tm1Jsv Genetic Background: B6.Cg-Fcgr2btm1Ttk Fcgr3tm1Jsv Fcer1atm1Knt Fcgr1tm1Jsv Fcer2atm1Max
|
MP:0005597 | decreased susceptibility to type I hypersensitivity reaction | "less likelihood or resistance to developing a response manifested by localized or generalized reaction that occurs immediately (minutes) after exposure to an antigen to which the person/animal was previously sensitized; it is IgE-mediated, and mast cell activation and degranulation are hallmarks" [Pathology:ISBN 0-397-51047-0, J:68588, cwg:Carroll-Ann W. Goldsmith , Mouse Genome Informatics curator] |
Show
Allelic Composition: Cd247tm1Lov/Cd247tm1Lov,Fcer1gtm1Rav/Fcer1gtm1Rav Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
MP:0008560 | increased tumor necrosis factor secretion | "increase in the production or release of a serum glycoprotein produced by activated macrophages and NK cells and involved in initiating local inflammatory responses, particularly by its action on the endothelium of local blood vessels; its actions result in increased vascular permeability and induction of expression of adhesion molecules on the endothelium" [ISBN:0-8153-1691-7 "Immunobiology, The Immune System in Health and Disease", MESH:D12.644.276.374.500.800] |
Show
Allelic Composition: Fcer1atm1Knt/Fcer1atm1Knt,Fcer2atm1Max/Fcer2atm1Max Genetic Background: B6.Cg-Fcer1atm1Knt Fcer2atm1Max
|
MP:0008603 | decreased circulating interleukin-4 level | "reduction in the amount in the blood of a soluble factor produced by activated T-cells that induces the expression of MHC class II genes and FC receptors on B-cells and causes their proliferation and differentiation; it also acts on T-cells, mast cells and several other hematopoietic lineage cells" [MESH:D12.644.276.374.465.504] |
Show
Allelic Composition: Fcer1atm1Ftl/Fcer1atm1Ftl Genetic Background: CBy.129S2-Fcer1atm1Ftl
|